{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:38:57Z","timestamp":1781239137826,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Baxalta GmbH, a wholly subsidiary of Takeda Pharmaceutical Company Limited","award":["IIR-FXX-002472"],"award-info":[{"award-number":["IIR-FXX-002472"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40261-023-01323-1","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T18:01:44Z","timestamp":1701367304000},"page":"35-49","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Key Drivers of Coagulation Factor Use in Von Willebrand Disease During Hospitalization: An Overview of the French BERHLINGO Cohort"],"prefix":"10.1007","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct03875924","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2988-5952","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Horvais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Beurrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8449-7995","authenticated-orcid":false,"given":"Vincent","family":"Cussac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9853-2635","authenticated-orcid":false,"given":"Brigitte","family":"Pan-Petesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4591-6197","authenticated-orcid":false,"given":"Sol\u00e8ne","family":"Schirr-Bonnans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9389-7045","authenticated-orcid":false,"given":"Johann","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Bayart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ternisien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0964-0739","authenticated-orcid":false,"given":"Marc","family":"Fouassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2005-1855","authenticated-orcid":false,"given":"Marianne","family":"Sigaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9284-7094","authenticated-orcid":false,"given":"Antoine","family":"Babuty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6500-5190","authenticated-orcid":false,"given":"Nicolas","family":"Drillaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2938-8013","authenticated-orcid":false,"given":"Beno\u00eet","family":"Guillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4072-839X","authenticated-orcid":false,"given":"Marc","family":"Trossa\u00ebrt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the BERHLINGO Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Cochennec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magalie","family":"Cornec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Drugmanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Galinat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Gouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Nedelec-Gac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"1323_CR1","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2017-05-782029","volume":"130","author":"R Sharma","year":"2017","unstructured":"Sharma R, Flood VH. Advances in the diagnosis and treatment of Von Willebrand disease. Blood. 2017;130:2386\u201391. https:\/\/doi.org\/10.1182\/blood-2017-05-782029.","journal-title":"Blood"},{"key":"1323_CR2","doi-asserted-by":"publisher","unstructured":"Fressinaud \u00c9. Clinical, biological and molecular diagnosis. H\u00e9matologie. 2014;30\u201349. DOI: https:\/\/doi.org\/10.1684\/hma.2014.0885","DOI":"10.1684\/hma.2014.0885"},{"key":"1323_CR3","unstructured":"Goodeve A, James P. von Willebrand disease. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, et al. editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [cited 2018 May 17]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK7014\/. Bookshelf ID: NBK7014."},{"key":"1323_CR4","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1177\/1076029616675969","volume":"23","author":"A Swami","year":"2017","unstructured":"Swami A, Kaur V. von Willebrand disease: a concise review and update for the practicing physician. Clin Appl Thromb Hemost. 2017;23:900\u201310. https:\/\/doi.org\/10.1177\/1076029616675969.","journal-title":"Clin Appl Thromb Hemost"},{"key":"1323_CR5","doi-asserted-by":"publisher","DOI":"10.1684\/hma.2014.0884","author":"P Boisseau","year":"2014","unstructured":"Boisseau P. Molecular genetic techniques. H\u00e9matologie. 2014. https:\/\/doi.org\/10.1684\/hma.2014.0884.","journal-title":"H\u00e9matologie"},{"key":"1323_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1055\/s-0037-1613992","volume":"84","author":"JE Sadler","year":"2000","unstructured":"Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84:160\u201374. https:\/\/doi.org\/10.1055\/s-0037-1613992.","journal-title":"Thromb Haemost"},{"key":"1323_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13473","author":"E Holm","year":"2018","unstructured":"Holm E, Carlsson KS, L\u00f6vdahl S, Lail AE, Abshire TC, Berntorp E. Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network. Haemophilia Internet. 2018. https:\/\/doi.org\/10.1111\/hae.13473.","journal-title":"Haemophilia Internet."},{"key":"1323_CR8","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1007\/s40265-017-0793-2","volume":"77","author":"JM Heijdra","year":"2017","unstructured":"Heijdra JM, Cnossen MH, Leebeek FWG. Current and Emerging Options for the Management of Inherited von Willebrand Disease. Drugs. 2017;77:1531\u201347. https:\/\/doi.org\/10.1007\/s40265-017-0793-2.","journal-title":"Drugs"},{"key":"1323_CR9","unstructured":"CRMW. Protocole National de Diagnostic et de Soins (PNDS)\u202f: Maladie de Willebrand type 3 [Internet]. HAS; 2021 Nov. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2022-01\/pnds_type_3_3_11_2021.pdf."},{"key":"1323_CR10","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1111\/j.1538-7836.2007.02588.x","volume":"5","author":"S Lethagen","year":"2007","unstructured":"Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM, FOR THE HAEMATE P\u00ae SURGICAL STUDY GROUP. von Willebrand factor\/factor VIII concentrate (Haemate\u00ae-P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost. 2007;5:1420\u201330. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02588.x.","journal-title":"J Thromb Haemost"},{"key":"1323_CR11","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/j.1365-2516.2011.02534.x","volume":"17","author":"JC Gill","year":"2011","unstructured":"Gill JC, Shapiro A, Valentino LA, Bernstein J, Friedman C, Nichols WL, et al. von Willebrand factor\/factor VIII concentrate (Humate\u00ae-P) for management of elective surgery in adults and children with von Willebrand disease: VWF\/FVIII concentrate in elective surgery. Haemophilia. 2011;17:895\u2013905. https:\/\/doi.org\/10.1111\/j.1365-2516.2011.02534.x.","journal-title":"Haemophilia"},{"key":"1323_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13451","author":"HCAM Hazendonk","year":"2018","unstructured":"Hazendonk HCAM, Heijdra JM, de Jager NCB, Veerman HC, Boender J, van Moort I, et al. Analysis of current perioperative management with Haemate\u00ae-P\/Humate\u00ae-P in von Willebrand disease: Identifying the need for personalized treatment. Haemophilia [Internet]. 2018. https:\/\/doi.org\/10.1111\/hae.13451.","journal-title":"Haemophilia [Internet]"},{"key":"1323_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.thromres.2014.12.017","volume":"135","author":"W Miesbach","year":"2015","unstructured":"Miesbach W, Krekeler S, Wolf Z, Seifried E. Clinical use of Haemate\u00ae-P in von Willebrand disease: a 25-year retrospective observational study. Thromb Res. 2015;135:479\u201384. https:\/\/doi.org\/10.1016\/j.thromres.2014.12.017.","journal-title":"Thromb Res"},{"key":"1323_CR14","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1160\/TH10-10-0631","volume":"105","author":"J Windyga","year":"2011","unstructured":"Windyga J, von Depka-Prondzinski M, the European Wilate\u00ae Study Group. Efficacy and safety of a new generation von Willebrand factor\/factor VIII concentrate (WILATE\u00ae) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery. Thromb Haemost. 2011;105:1072\u20139. https:\/\/doi.org\/10.1160\/TH10-10-0631.","journal-title":"Thromb Haemost"},{"key":"1323_CR15","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/j.1538-7836.2007.02562","volume":"5","author":"A Borel-Derlon","year":"2007","unstructured":"Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I, et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin\u00ae): a prospective study of 50 patients. J Thromb Haemost. 2007;5:1115\u201324. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02562.","journal-title":"J Thromb Haemost"},{"key":"1323_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/hae.13106","volume":"23","author":"A Srivastava","year":"2017","unstructured":"Srivastava A, Serban M, Werner S, Schwartz BA, Kessler CM, the Wonders Study Investigators. Efficacy and safety of a VWF\/FVIII concentrate (WILATE\u00ae) in inherited von Willebrand disease patients undergoing surgical procedures. Haemophilia. 2017;23:264\u201372. https:\/\/doi.org\/10.1111\/hae.13106.","journal-title":"Haemophilia"},{"key":"1323_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.30809\/phe.2.2015.4","volume":"3","author":"AU Kulikov","year":"2015","unstructured":"Kulikov AU, Babiy VV. Pharmacoeconomic analysis of von Willebrand factor\/blood clotting factor VIII Concentrate (WILATE\u00ae) in the management of patients with Von Willebrand disease. Pharmacoecon Theory Pract. 2015;3:74\u201381. https:\/\/doi.org\/10.30809\/phe.2.2015.4.","journal-title":"Pharmacoecon Theory Pract"},{"key":"1323_CR18","doi-asserted-by":"publisher","first-page":"A530","DOI":"10.1016\/j.jval.2014.08.1681","volume":"17","author":"A Cipolla","year":"2014","unstructured":"Cipolla A, Cultrera D, Teruzzi C, Mantuano M. Cost-consequences analysis of the long-term prophylaxis in a type 1 Von Willebrand disease patient with recurrent bleedings in Italy. Value Health. 2014;17:A530. https:\/\/doi.org\/10.1016\/j.jval.2014.08.1681.","journal-title":"Value Health."},{"key":"1323_CR19","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S71892","author":"C Teruzzi","year":"2014","unstructured":"Teruzzi C, Schinco P, Cultrera D, Valeri F, Borchiellini A, Mantuano M, et al. Cost-consequence analysis of long-term prophylaxis in the treatment of von Willebrand disease in the Italian context. Clinicoecon Outcomes Res. 2014. https:\/\/doi.org\/10.2147\/CEOR.S71892.","journal-title":"Clinicoecon Outcomes Res."},{"key":"1323_CR20","doi-asserted-by":"publisher","unstructured":"Schinco P, Castaman G, Coppola A, Cultrera D, Ettorre C, Giuffrida AC, et al. Current challenges in the diagnosis and management of patients with inherited von Willebrand\u2019s disease in Italy: an Expert Meeting Report on the diagnosis and surgical and secondary long-term prophylaxis. Blood Transfus [Internet]. 2017 [cited 2018 May 16]; http:\/\/www.bloodtransfusion.it\/articolosing.aspx?id=000935. DOI: https:\/\/doi.org\/10.2450\/2017.0354-16.","DOI":"10.2450\/2017.0354-16"},{"key":"1323_CR21","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X.","journal-title":"Lancet"},{"key":"1323_CR22","unstructured":"INSEE R. INSEE - \u00c9volution g\u00e9n\u00e9rale de la situation d\u00e9mographique par d\u00e9partement et r\u00e9gion - S\u00e9ries depuis 1990 (Bretagne & Pays-de-Loire) [Internet]. 2020 [cited 2021 Dec 16]. https:\/\/www.insee.fr\/fr\/statistiques\/fichier\/4503164\/p1d.xlsx."},{"key":"1323_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/hae.12406","volume":"20","author":"G Dolan","year":"2014","unstructured":"Dolan G, Makris M, Bolton-Maggs PHB, Rowell JA. Enhancing haemophilia care through registries. Haemophilia. 2014;20:121\u20139. https:\/\/doi.org\/10.1111\/hae.12406.","journal-title":"Haemophilia"},{"key":"1323_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40290-020-00332-1","volume":"34","author":"V Boulanger","year":"2020","unstructured":"Boulanger V, Schlemmer M, Rossov S, Seebald A, Gavin P. Establishing patient registries for rare diseases: rationale and challenges. Pharm Med. 2020;34:185\u201390. https:\/\/doi.org\/10.1007\/s40290-020-00332-1.","journal-title":"Pharm Med."},{"key":"1323_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.924648","volume":"13","author":"CJ Jonker","year":"2022","unstructured":"Jonker CJ, Bakker E, Kurz X, Plueschke K. Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe. Front Pharmacol. 2022;13: 924648. https:\/\/doi.org\/10.3389\/fphar.2022.924648.","journal-title":"Front Pharmacol"},{"key":"1323_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003038","volume":"95","author":"A Veyradier","year":"2016","unstructured":"Veyradier A, Boisseau P, Fressinaud E, Caron C, Ternisien C, Giraud M, et al. A laboratory phenotype\/genotype correlation of 1167 French patients from 670 families with von Willebrand Disease: a new epidemiologic picture. Medicine (Baltimore). 2016;95: e3038. https:\/\/doi.org\/10.1097\/MD.0000000000003038.","journal-title":"Medicine (Baltimore)"},{"key":"1323_CR27","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1055\/s-0031-1281037","volume":"37","author":"A Federici","year":"2011","unstructured":"Federici A, Bucciarelli P, Castaman G, Baronciani L, Canciani M, Mazzucconi M, et al. Management of inherited von Willebrand disease in italy: results from the retrospective study on 1234 patients. Semin Thromb Hemost. 2011;37:511\u201321. https:\/\/doi.org\/10.1055\/s-0031-1281037.","journal-title":"Semin Thromb Hemost"},{"key":"1323_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1160\/TH15-04-0282","volume":"115","author":"J Batlle","year":"2016","unstructured":"Batlle J, P\u00e9rez-Rodr\u00edguez A, Corrales I, L\u00f3pez-Fern\u00e1ndez MF, Rodr\u00edguez-Trillo \u00c1, Lour\u00e9s E, et al. Molecular and clinical profile of von Willebrand disease in Spain (PCM\u2013EVW\u2013ES): proposal for a new diagnostic paradigm. Thromb Haemost. 2016;115:40\u201350. https:\/\/doi.org\/10.1160\/TH15-04-0282.","journal-title":"Thromb Haemost"},{"key":"1323_CR29","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1111\/jth.14928","volume":"18","author":"J Goudemand","year":"2020","unstructured":"Goudemand J, Bridey F, Claeyssens S, Itzhar-Ba\u00efkian N, Harroche A, Desprez D, et al. Management of von Willebrand disease with a factor VIII-poor von Willebrand factor concentrate: Results from a prospective observational post-marketing study. J Thromb Haemost. 2020;18:1922\u201333. https:\/\/doi.org\/10.1111\/jth.14928.","journal-title":"J Thromb Haemost"},{"key":"1323_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1046\/j.1365-2516.1998.0040s3048.x","volume":"4","author":"N Goudemand","year":"1998","unstructured":"Goudemand N, Ounnoughene S. Clinical management of patients with von Willebrand\u2019s disease with a VHP vWF concentrate: the French experience: treatment of von Willebrand\u2019s disease. Haemophilia. 1998;4:48\u201352. https:\/\/doi.org\/10.1046\/j.1365-2516.1998.0040s3048.x.","journal-title":"Haemophilia"},{"issue":"2","key":"1323_CR31","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2450\/2020.0246-20","volume":"19","author":"L Rugeri","year":"2021","unstructured":"Rugeri L, d\u2019Oiron R, Harroche A, Proulle V, Mourey G, De Raucourt E, Desprez D, Baikian NI, Petesch BP, Borel-Derlon A, Combe S, Frotscher B, Hassoun A, Catovic H, Bracquart D, Trossa\u00ebrt M. Effectiveness and safety of hFVIII\/VWF concentrate (Voncento\u00ae) in patients with inherited von Willebrand disease requiring surgical procedures: the OPALE multicentre observational study. Blood Transfus. 2021;19(2):152\u20137. https:\/\/doi.org\/10.2450\/2020.0246-20. (Epub 2020 Nov 27. PMID: 33263522; PMCID: PMC7925218).","journal-title":"Blood Transfus"},{"key":"1323_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1365-2516.2009.02088.x","volume":"16","author":"AB Federici","year":"2010","unstructured":"Federici AB, Barillari G, Zanon E, Mazzucconi MG, Musso R, Targhetta R, et al. Efficacy and safety of highly purified, doubly virus-inactivated VWF\/FVIII concentrates in inherited von Willebrand\u2019s disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score. Haemophilia. 2010;16:101\u201310. https:\/\/doi.org\/10.1111\/j.1365-2516.2009.02088.x.","journal-title":"Haemophilia"},{"key":"1323_CR33","doi-asserted-by":"publisher","first-page":"107602962311770","DOI":"10.1177\/10760296231177023","volume":"29","author":"E Swallow","year":"2023","unstructured":"Swallow E, Marden JR, Billmyer E, Yim E, Sun SX. Burden of illness and treatment patterns among patients with von willebrand disease in US Clinical Practice. Clin Appl Thromb Hemost. 2023;29:107602962311770.","journal-title":"Clin Appl Thromb Hemost"},{"key":"1323_CR34","unstructured":"ATIH. ENC MCO. Analyse de l\u2019ensemble des s\u00e9jours\u202f: co\u00fbt moyen d\u2019un s\u00e9jour en 2018 [Internet]. ATIH; 2018. https:\/\/www.scansante.fr\/applications\/enc-mco\/submit?snatnav=&annee=2018&secteur=dgf&type_activite=ghs&cmd=&souscmd=&racine=&ghm=TOTAL&mbout=dummy&num_selection=TOTAL&type_selection=ghm&zip=non."},{"key":"1323_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.healthpol.2021.12.004","volume":"126","author":"K Jacobs","year":"2022","unstructured":"Jacobs K, Roman E, Lambert J, Moke L, Scheys L, Kesteloot K, et al. Variability drivers of treatment costs in hospitals: A systematic review. Health Policy. 2022;126:75\u201386. https:\/\/doi.org\/10.1016\/j.healthpol.2021.12.004.","journal-title":"Health Policy"},{"key":"1323_CR36","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1016\/j.respe.2020.04.028","volume":"68","author":"A Duburcq","year":"2020","unstructured":"Duburcq A, Courouve L, Mercier C, Scherman D, L\u00e9vy P, Bahi-Buisson N, et al. Co\u00fbt des maladies rares en France en 2017: une analyse des donn\u00e9es du Syst\u00e8me national des donn\u00e9es de sant\u00e9 sur cinq pathologies. Rev Epidemiol Sante Publique. 2020;68:S76\u20137. https:\/\/doi.org\/10.1016\/j.respe.2020.04.028.","journal-title":"Rev Epidemiol Sante Publique"},{"key":"1323_CR37","unstructured":"Colin C, Couray-Targe S, Lo\u00efc G. PMSI\u202f: Quelles comparaisons possibles et impossibles\u202f? ADSP. 2000; Organisation, d\u00e9cision et financement du syst\u00e8me de soins:53\u20135. ISSN: 1243-275X"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01323-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01323-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01323-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T12:32:39Z","timestamp":1704457959000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01323-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1323"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01323-1","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]},"assertion":[{"value":"29 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Declarations"}},{"value":"This study was funded by Baxalta GmbH, a wholly subsidiary of Takeda Pharmaceutical Company Limited, as part of an investigator-initiated research project (IIR-FXX-002472). Baxalta GmbH played no role in the design and conduct of the study\/collection, management, analysis, or interpretation of the data\/preparation, writing, review, or approval of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Val\u00e9rie Horvais, Philippe Beurrier, Vincent Cussac, Brigitte Pan-Petesch, Sol\u00e8ne Schirr-Bonnans, Johann Rose, Sophie Bayart, Catherine Ternisien, Marc Fouassier, Marianne Sigaud, Antoine Babuty and Nicolas Drillaud declare that they have no conflict of interest. Beno\u00eet Guillet received research grants from CSL Behring and consulting fees from CSL Behring\/LFB\/Takeda. Marc Trossa\u00ebrt received funding from Baxalta GmbH for the Hopscotch Will I study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The data underlying the findings of this study are not openly available because they are sensitive. They can be obtained from the corresponding author upon reasonable request. The data are stored in a controlled access facility at Nantes University Hospital.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The Institutional Ethics Committee approved the study protocol on 3 April 2019 (<i>Groupe Nantais d'Ethique dans le Domaine de la Sant\u00e9<\/i>, GNEDS).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"The patient's non-objection was required for inclusion in the study. No written consent was required.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Val\u00e9rie Horvais, Sol\u00e8ne Schirr-Bonnans and Marc Trossa\u00ebrt contributed to the conception and design of the study. All of the authors contributed to the preparation of the materials and collection of the data. The analyses were performed by Val\u00e9rie Horvais and Sol\u00e8ne Schirr-Bonnans. The first draft of the manuscript was written by Val\u00e9rie Horvais and all authors commented on all intermediary versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}